[A Case of Locally Advanced Colorectal Cancer with Severe Bladder Invasion Successfully Treated with Preoperative Chemotherapy with Anti-EGFR Antibody and Avoiding Total Bladder Resection].

Q4 Medicine
Jyunta Hayashi, Kiichi Sugimoto, Saki Kochi, Miyuki Toake, Hiromitsu Takahashi, Takahiro Irie, Hirotaka Momose, Kota Amemiya, Yuki Tsuchiya, Ryoichi Tsukamoto, Hisashi Ro, Kumpei Honjo, Masaya Kawai, Shun Ishiyama, Kazuhiro Sakamoto
{"title":"[A Case of Locally Advanced Colorectal Cancer with Severe Bladder Invasion Successfully Treated with Preoperative Chemotherapy with Anti-EGFR Antibody and Avoiding Total Bladder Resection].","authors":"Jyunta Hayashi, Kiichi Sugimoto, Saki Kochi, Miyuki Toake, Hiromitsu Takahashi, Takahiro Irie, Hirotaka Momose, Kota Amemiya, Yuki Tsuchiya, Ryoichi Tsukamoto, Hisashi Ro, Kumpei Honjo, Masaya Kawai, Shun Ishiyama, Kazuhiro Sakamoto","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, the efficacy of preoperative treatment for locally advanced colorectal cancer has been reported to improve surgical cure rates and decrease postoperative recurrence rates. In this study, we report a case of locally advanced colorectal cancer with severe bladder invasion that responded to preoperative chemotherapy with an anti-EGFR antibody, resulting in the avoidance of total bladder resection. After diverting colostomy to change the bowel route, the patient underwent 5 courses of mFOLFOX6 therapy and 3 courses of mFOLFOX6 + cetuximab therapy to preserve bladder integrity. After confirming tumor shrinkage through imaging, laparoscopic high-level anterior resection and partial bladder resection were performed, allowing for R0 resection and bladder preservation. Approximately 4 years have passed since the resection of the primary tumor, and there has been no recurrence of the primary disease. Therefore, the indications and efficacy of preoperative treatment with molecularly targeted drugs, including anti-EGFR antibody drugs, for locally advanced colorectal cancer should be investigated in a prospective clinical trial.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"307-309"},"PeriodicalIF":0.0000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In recent years, the efficacy of preoperative treatment for locally advanced colorectal cancer has been reported to improve surgical cure rates and decrease postoperative recurrence rates. In this study, we report a case of locally advanced colorectal cancer with severe bladder invasion that responded to preoperative chemotherapy with an anti-EGFR antibody, resulting in the avoidance of total bladder resection. After diverting colostomy to change the bowel route, the patient underwent 5 courses of mFOLFOX6 therapy and 3 courses of mFOLFOX6 + cetuximab therapy to preserve bladder integrity. After confirming tumor shrinkage through imaging, laparoscopic high-level anterior resection and partial bladder resection were performed, allowing for R0 resection and bladder preservation. Approximately 4 years have passed since the resection of the primary tumor, and there has been no recurrence of the primary disease. Therefore, the indications and efficacy of preoperative treatment with molecularly targeted drugs, including anti-EGFR antibody drugs, for locally advanced colorectal cancer should be investigated in a prospective clinical trial.

【局部晚期结直肠癌伴严重膀胱侵犯术前抗egfr抗体化疗避免全膀胱切除成功1例】。
近年来,局部晚期结直肠癌术前治疗的疗效提高了手术治愈率,降低了术后复发率。在这项研究中,我们报告了一例局部晚期结直肠癌伴严重膀胱侵犯的病例,该病例对术前抗egfr抗体化疗有反应,导致避免了全膀胱切除术。患者在转移结肠造口改变肠路后,接受了5个疗程的mFOLFOX6治疗和3个疗程的mFOLFOX6 +西妥昔单抗治疗,以保持膀胱完整性。经影像学确认肿瘤缩小后,行腹腔镜高位前切除术和膀胱部分切除术,以R0切除和膀胱保留。原发肿瘤切除约4年,原发疾病未复发。因此,局部晚期结直肠癌术前应用分子靶向药物(包括抗egfr抗体药物)治疗的适应症和疗效需要进行前瞻性临床试验研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
337
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书